泛素特异性蛋白酶22与原发性中枢神经系统淋巴瘤预后的关系  

Effects of the ubiquitin-specific protease 22 in primary central nervous system lymphoma

作　　者：郑杰 刘英丽 康进生[3] 崔雪花 桑琳霞[1] 李文玲[1] ZHENG Jie;LIU Yingli;KANG Jinsheng;CUI Xuehua;SANG Linxia;LI Wenling(Department of Neurosurgery,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Department of Epidemiology and Statistics,School of Public Health,Hebei Medical University,Shijiazhuang 050017,China;Department of No.2 Neurosurgery,Hebei General Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学第二医院神经外科,石家庄050000 [2]河北医科大学公共卫生学院流行病与卫生统计学教研室,石家庄050017 [3]河北省人民医院神经外二科,石家庄050051

出　　处：《中国医科大学学报》2020年第12期1091-1094,1100,共5页Journal of China Medical University

基　　金：河北省医学科学研究重点课题(20180110)。

摘　　要：目的探讨泛素特异性蛋白酶22(USP22)在原发性中枢神经系统淋巴瘤(PCNSL)预后中的作用。方法收集48例PCNSL患者脑组织,同时收集27例脑挫裂伤患者挫伤灶脑组织。采用实时荧光定量PCR(qRT-PCR)和Western blotting检测USP22 mRNA和蛋白的表达情况,并采用Kaplan-Meier法和Cox模型探讨USP22对PCNSL患者预后的影响。结果qRT-PCR和Western blotting的结果显示,PCNSL组织中USP22 mRNA和蛋白的表达水平均高于挫伤灶脑组织(P<0.05)。随着USP22蛋白表达水平升高,肿瘤的大小和数量也相应增加。生存分析结果显示,USP22蛋白表达水平越高,患者预后越差(P<0.05)。结论USP22高表达与PCNSL的不良预后密切相关,今后可作为治疗的靶点以改善PCNSL患者的预后。Objective To explore the effects of the ubiquitin-specific protease 22(USP22)in patients with primary central nervous system lymphoma(PCNSL).Methods Brain tissues from 48 patients with PCNSL and 27 patients with cerebral contusion were collected.The expression of USP22 mRNA and protein were measured using quantitative real-time PCR(qRT-PCR)and Western blotting,and the effects of USP22 on the prognosis of PCNSL were explored using Kaplan-Meier method and Cox model.Results The expression of USP22 mRNA and protein in PCNSL tissues was higher than that in the cerebral tissues with contusion(P<0.05).The expression of USP22 was identified to be correlated with tumor size and the number of lesions,and the prognosis of PCNSL in patients with high USP22 expression was poor(P<0.05).Conclusion The high expression of USP22 is closely related to the poor prognosis of PCNSL,and USP22 is a potential therapeutic target.

关 键 词：原发性中枢神经系统淋巴瘤 泛素特异性蛋白酶22 预后 

分 类 号：R739.41[医药卫生—肿瘤]